85 related articles for article (PubMed ID: 25417604)
1. Bevicizumab and thrombosis: some answers but questions remain.
DeLoughery TG; Beer TM
Cancer; 2015 Apr; 121(7):975-7. PubMed ID: 25417604
[No Abstract] [Full Text] [Related]
2. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Patel JN; Jiang C; Hertz DL; Mulkey FA; Owzar K; Halabi S; Ratain MJ; Friedman PN; Small EJ; Carducci MA; Mahoney JF; Kelley MJ; Morris MJ; Kelly WK; McLeod HL
Cancer; 2015 Apr; 121(7):1025-31. PubMed ID: 25417775
[TBL] [Abstract][Full Text] [Related]
3. Moving the goal posts in prostate cancer trials.
Madan RA; Gulley JL
Lancet Oncol; 2015 Mar; 16(3):247-9. PubMed ID: 25701172
[No Abstract] [Full Text] [Related]
4. The evolving role of chemotherapy in prostate cancer.
Saad F
Curr Opin Support Palliat Care; 2016 Sep; 10(3):262-5. PubMed ID: 27489183
[No Abstract] [Full Text] [Related]
5. Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Khanna A; Reece-Smith AM; Cunnell M; Madhusudan S; Thomas A; Bowrey DJ; Parsons SL
Dis Esophagus; 2014 Apr; 27(3):242-7. PubMed ID: 23651074
[TBL] [Abstract][Full Text] [Related]
6. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.
Winquist E; Julian JA; Moore MJ; Nabid A; Sathya J; Wood L; Venner P; Levine M
J Clin Oncol; 2009 Feb; 27(4):644-6. PubMed ID: 19103725
[No Abstract] [Full Text] [Related]
8. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.
Heidenreich A; Pfister D; Merseburger A; Bartsch G;
Eur Urol; 2013 Aug; 64(2):260-5. PubMed ID: 23706522
[No Abstract] [Full Text] [Related]
9. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
10. Secondary acute myelogenous leukemia following treatment with oral etoposide.
Katato K; Flaherty L; Varterasian M
Am J Hematol; 1996 Sep; 53(1):54-5. PubMed ID: 8813107
[No Abstract] [Full Text] [Related]
11. Risk of venous thromboembolism with bevacizumab in cancer patients.
Kilickap S; Arslan C
JAMA; 2009 Apr; 301(14):1435; author reply 1435-6. PubMed ID: 19351938
[No Abstract] [Full Text] [Related]
12. What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?
Steineck G; Glimelius B
Acta Oncol; 2013 Nov; 52(8):1589-92. PubMed ID: 24102178
[No Abstract] [Full Text] [Related]
13. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
Jang HS; Koo KC; Cho KS; Chung BH
Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
Lupera H; Droz JP; Piot G; Lapleige P; Fargeot P; Theodore C
Oncology; 1989; 46(6):372-4. PubMed ID: 2587004
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous chylothorax and chylous ascites in a patient with castration-resistant prostate cancer after docetaxel chemotherapy: An unusual manifestation.
Shimizu Y; Kanamaru S; Ito N
Int J Urol; 2015 Jun; 22(6):614. PubMed ID: 25854536
[No Abstract] [Full Text] [Related]
16. The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.
Orsola A; Bellmunt J
Eur Urol; 2015 Jan; 67(1):30-32. PubMed ID: 25108578
[No Abstract] [Full Text] [Related]
17. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
18. [Dexamethasone therapy for castration-resistant prostate cancer].
Nishimura K
Nihon Rinsho; 2016 May; 74 Suppl 3():601-4. PubMed ID: 27344801
[No Abstract] [Full Text] [Related]
19. Intermittent androgen deprivation therapy: clarity from confusion.
Klotz L
Eur Urol; 2013 Nov; 64(5):731-3. PubMed ID: 23866956
[No Abstract] [Full Text] [Related]
20. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Yuasa T
Int J Urol; 2009 Sep; 16(9):731-2. PubMed ID: 19769657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
